SEC Form 4 · accession 0001209191-16-095844
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul M Silva
Officer — SVP & Corp Controller
Period of report
Feb 2, 2016
Accepted (ET)
Feb 4, 2016 · 6:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 2, 2016 | A | 6,875 | $0.01 | A | 21,812 | D | |
| Common StockF3,F4 | Feb 3, 2016 | S | 2,300 | $89.96 | D | 19,512 | D | |
| Common StockF4,F5 | Feb 3, 2016 | S | 1,900 | $91.07 | D | 17,612 | D | |
| Common StockF4,F6 | Feb 3, 2016 | S | 662 | $92.43 | D | 16,950 | D | |
| Common StockF4,F7 | Feb 3, 2016 | S | 200 | $93.06 | D | 16,750 | D | |
| Common Stock | holding | — | — | — | 169 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F8 | $91.05 | Feb 2, 2016 | A | 20,625 | A | — | Feb 1, 2026 | Common Stock | 20,625 | 20,625 | D |
Explanation of responses
- F1Restricted stock grant vesting on 2/2/2019, subject to acceleration if certain financial and/or business metrics are achieved.
- F2Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
- F3Open market sales reported on this line occurred at a weighted average price of $89.96 (range $89.54 to $90.44).
- F4Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F5Open market sales reported on this line occurred at a weighted average price of $91.07 (range $90.56 to $91.48).
- F6Open market sales reported on this line occurred at a weighted average price of $92.43 (range $91.79 to $92.72).
- F7Open market sales reported on this line occurred at a weighted average price of $93.06 (range $92.98 to $93.14).
- F8The option vests in 16 quarterly installments from 02/02/2016.